Literature DB >> 26906561

Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use.

Anthony J Culyer1.   

Abstract

There is misunderstanding about both the meaning and the role of cost-effectiveness thresholds in policy decision making. This article dissects the main issues by use of a bookshelf metaphor. Its main conclusions are as follows: it must be possible to compare interventions in terms of their impact on a common measure of health; mere effectiveness is not a persuasive case for inclusion in public insurance plans; public health advocates need to address issues of relative effectiveness; a 'first best' benchmark or threshold ratio of health gain to expenditure identifies the least effective intervention that should be included in a public insurance plan; the reciprocal of this ratio - the 'first best' cost-effectiveness threshold - will rise or fall as the health budget rises or falls (ceteris paribus); setting thresholds too high or too low costs lives; failure to set any cost-effectiveness threshold at all also involves avertable deaths and morbidity; the threshold cannot be set independently of the health budget; the threshold can be approached from either the demand side or the supply side - the two are equivalent only in a health-maximising equilibrium; the supply-side approach generates an estimate of a 'second best' cost-effectiveness threshold that is higher than the 'first best'; the second best threshold is the one generally to be preferred in decisions about adding or subtracting interventions in an established public insurance package; multiple thresholds are implied by systems having distinct and separable health budgets; disinvestment involves eliminating effective technologies from the insured bundle; differential weighting of beneficiaries' health gains may affect the threshold; anonymity and identity are factors that may affect the interpretation of the threshold; the true opportunity cost of health care in a community, where the effectiveness of interventions is determined by their impact on health, is not to be measured in money - but in health itself.

Entities:  

Mesh:

Year:  2016        PMID: 26906561     DOI: 10.1017/S1744133116000049

Source DB:  PubMed          Journal:  Health Econ Policy Law        ISSN: 1744-1331


  25 in total

1.  Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water.

Authors:  Mattias Neyt
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

Review 2.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

3.  Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study.

Authors:  Sebastian Hinde; Dan Howdon; James Lomas; Matthew Franklin
Journal:  Appl Health Econ Health Policy       Date:  2022-06-29       Impact factor: 2.561

4.  A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African Nations.

Authors:  David Watkins; Solomon J Lubinga; Bongani Mayosi; Joseph B Babigumira
Journal:  PLoS Negl Trop Dis       Date:  2016-08-11

5.  We need a NICE for global development spending.

Authors:  Kalipso Chalkidou; Anthony J Culyer; Amanda Glassman; Ryan Li
Journal:  F1000Res       Date:  2017-07-25

6.  Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness".

Authors:  Kalipso Chalkidou; Ryan Li; Anthony J Culyer; Amanda Glassman; Karen J Hofman; Yot Teerawattananon
Journal:  Int J Health Policy Manag       Date:  2017-04-01

7.  The (Ir)relevance of Group Size in Health Care Priority Setting: A Reply to Juth.

Authors:  Lars Sandman; Erik Gustavsson
Journal:  Health Care Anal       Date:  2017-03

8.  Supporting the development of a health benefits package in Malawi.

Authors:  Jessica Ochalek; Paul Revill; Gerald Manthalu; Finn McGuire; Dominic Nkhoma; Alexandra Rollinger; Mark Sculpher; Karl Claxton
Journal:  BMJ Glob Health       Date:  2018-04-09

9.  National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India.

Authors:  Shankar Prinja; Yashika Chugh; Kavitha Rajsekar; V R Muraleedharan
Journal:  Appl Health Econ Health Policy       Date:  2021-06-29       Impact factor: 2.561

10.  Cost-effectiveness of seasonal malaria chemoprevention in upper west region of Ghana.

Authors:  Justice Nonvignon; Genevieve Cecilia Aryeetey; Shamwill Issah; Patrick Ansah; Keziah L Malm; Winfred Ofosu; Titus Tagoe; Samuel Agyei Agyemang; Moses Aikins
Journal:  Malar J       Date:  2016-07-16       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.